Grant of Options and Extension of Warrant Term

AI SummaryClose X

Hemogenyx Pharmaceuticals plc announced the grant of 1,200,000 ordinary share options to its Non-Executive and Executive Directors, and an additional 60,000 options to employees, all with an exercise price of £8 and expiring on 29 May 2031. Following these grants, a total of 1,410,479 shares are under option, representing 20.7% of the issued share capital. Additionally, the company has extended the term of 69,048 investor warrants from their original grant date of 8 March 2025 to 7 September 2026, aligning them with other existing warrants without changing the exercise price.

Disclaimer*

UK 100

Latest directors dealings